| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01157065 | Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration | PHASE2 | COMPLETED | 99 | — | — | Jun 1, 2011 | Apr 1, 2012 | Jun 4, 2013 | 1 | United States |
The thickness of the retina was measured using a non-invasive device that produces cross-sectional and 3D images of the eye. The reduction was calculated by subtracting Week 4 visit value from the Baseline value. A positive number indicates a reduction in thickness compared to baseline, whereas a negative number indicates an increase in thickness. An increase in thickness as compared to baseline may indicate a progression of the underlying disease.
An ESI was a protocol-specified event of scientific and medical concern specific to the Sponsor's product or program where ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. These adverse events could have been serious or nonserious and may have required further investigation in order to characterize and understand.
| Arm | Type | Description |
|---|---|---|
| AL-78898A | EXPERIMENTAL | Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up |
| Lucentis | ACTIVE_COMPARATOR | Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up |
| Name | Type | Description |
|---|---|---|
| AL-78898A | DRUG | Investigational treatment |
| Ranibizumab | DRUG | Anti-vascular endothelial growth factor (VEGF) treatment |
Inclusion Criteria: * Willing to give informed consent, make the required study visits and follow instructions; * Newly diagnosed with exudative age-related macular degeneration (AMD); * Presence of primary juxta- or subfoveal choroidal neovascularization (CNV) secondary to AMD (study eye); * Best-...